Skip to main content
Journal cover image

Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.

Publication ,  Journal Article
Wang, W; Hong, GJ; Stinnett, SS; Freedman, SF; Wallace, DK; Prakalapakorn, SG
Published in: J AAPOS
December 2022

Current therapies for treatment-indicated (type 1) retinopathy of prematurity mainly consist of laser photocoagulation and intravitreal anti-vascular endothelial growth factor (eg, bevacizumab) injection. The first visible signs of acute-phase regression are typically vascular, including decreased plus disease. Using a semiautomated computer program, we quantitatively compared posterior pole vascular changes following treatment with laser versus bevacizumab and found that in the first month following treatment, vascular dilation and tortuosity significantly decreased following either treatment modality, but tortuosity decreased earlier and faster after bevacizumab.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J AAPOS

DOI

EISSN

1528-3933

Publication Date

December 2022

Volume

26

Issue

6

Start / End Page

323 / 326

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Retinopathy of Prematurity
  • Ophthalmology & Optometry
  • Lasers
  • Laser Coagulation
  • Intravitreal Injections
  • Infant, Newborn
  • Humans
  • Gestational Age
  • Combined Modality Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, W., Hong, G. J., Stinnett, S. S., Freedman, S. F., Wallace, D. K., & Prakalapakorn, S. G. (2022). Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab. J AAPOS, 26(6), 323–326. https://doi.org/10.1016/j.jaapos.2022.08.261
Wang, Weiliang, Gloria J. Hong, Sandra S. Stinnett, Sharon F. Freedman, David K. Wallace, and S Grace Prakalapakorn. “Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.J AAPOS 26, no. 6 (December 2022): 323–26. https://doi.org/10.1016/j.jaapos.2022.08.261.
Wang W, Hong GJ, Stinnett SS, Freedman SF, Wallace DK, Prakalapakorn SG. Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab. J AAPOS. 2022 Dec;26(6):323–6.
Wang, Weiliang, et al. “Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab.J AAPOS, vol. 26, no. 6, Dec. 2022, pp. 323–26. Pubmed, doi:10.1016/j.jaapos.2022.08.261.
Wang W, Hong GJ, Stinnett SS, Freedman SF, Wallace DK, Prakalapakorn SG. Quantitative comparison of blood vessel changes after treatment of retinopathy of prematurity with laser versus bevacizumab. J AAPOS. 2022 Dec;26(6):323–326.
Journal cover image

Published In

J AAPOS

DOI

EISSN

1528-3933

Publication Date

December 2022

Volume

26

Issue

6

Start / End Page

323 / 326

Location

United States

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Retinopathy of Prematurity
  • Ophthalmology & Optometry
  • Lasers
  • Laser Coagulation
  • Intravitreal Injections
  • Infant, Newborn
  • Humans
  • Gestational Age
  • Combined Modality Therapy